Pfizer raised the lower end of its 2026 revenue guidance on Tuesday, August 4, after second-quarter sales and adjusted earnings beat Wall Street expectations. The drugmaker now expects $60.5 billion to $62.5 billion in annual revenue while targeting $9.7 billion of total net cost savings through 2029—a restructuring drive designed to protect profits as COVID sales collapse and major medicines approach patent expiration.
The PFE stock price rose about 1.5% to $25.41 after the report, giving Pfizer a market capitalization near $146 billion. The immediate reaction strengthens the near-term stock forecast, but the company still must prove that savings, oncology products, and its obesity pipeline can create genuine growth rather than merely soften an approaching revenue cliff.
Pfizer Earnings Beat as Eliquis Powers Past Expectations
Pfizer generated second-quarter revenue of $15.03 billion, approximately 3% higher than a year earlier and comfortably above Wall Street’s roughly $14.4 billion estimate.
Adjusted earnings reached $0.77 per share, beating the consensus forecast by $0.09. That represented an adjusted earnings surprise of about 13%, giving investors evidence that Pfizer’s commercial portfolio and spending controls are performing better than feared.
Blood thinner Eliquis was the quarter’s biggest engine.
The company’s share of Eliquis revenue rose about 21% to $2.43 billion, far above the approximately $1.93 billion analysts expected. The medicine, which Pfizer markets with Bristol Myers Squibb, helped compensate for plunging demand for pandemic products.
Vyndaqel-family revenue also climbed, supported by demand for treatments used in transthyretin amyloid cardiomyopathy. Oncology products acquired through Pfizer’s $43 billion Seagen takeover supplied another important source of growth.
Padcev sales increased 23% to $667 million, exceeding expectations near $634 million. Lorbrena and several other cancer medicines also contributed to the revenue beat, showing that Pfizer’s post-pandemic portfolio is becoming broader even before its most closely watched pipeline assets reach the market.
Pfizer Stock Forecast Improves After Revenue Guidance Raise
Management lifted the bottom end of its full-year revenue forecast by $1 billion.
Pfizer now expects 2026 sales between $60.5 billion and $62.5 billion, compared with its previous range of $59.5 billion to $62.5 billion. The midpoint increased from $61 billion to $61.5 billion.
The revision reflects stronger expectations for Pfizer’s non-COVID portfolio.
Management increased its anticipated revenue from non-pandemic products by approximately $1.5 billion. However, that improvement was partly offset by a reduction in the expected contribution from COVID products, which fell from roughly $5 billion to $4 billion.
Pfizer maintained its adjusted earnings guidance of $2.80 to $3 per share despite absorbing a $650 million upfront payment connected to an oncology licensing agreement with China’s Innovent Biologics.
Holding the profit forecast while funding additional pipeline investment is encouraging. It suggests cost reductions and stronger product sales are creating enough flexibility to support research without forcing management to lower near-term earnings expectations.
Still, the upgraded revenue range is not an aggressive growth forecast.
At the midpoint, Pfizer’s sales outlook remains close to the approximately $62 billion the company recorded in 2025. Investors are therefore receiving improved downside protection, not yet a clear return to sustained top-line expansion.
Pfizer Targets $9.7 Billion in Net Cost Savings
The most dramatic announcement was Pfizer’s expansion of its restructuring program.
The company added another $2.5 billion of planned savings, taking its total expected net reductions to approximately $9.7 billion through 2029. The initiative includes administrative efficiencies, manufacturing changes, organizational simplification, and lower sales and marketing expenses.
Chief Executive Albert Bourla said Pfizer reduced administrative, sales, and marketing costs by 3% during the first half of 2026 while increasing research and development spending by 12%.
That allocation is strategically important.
Pfizer is not presenting the program simply as an across-the-board spending freeze. Management says it is removing costs from corporate functions such as finance, legal, and human resources while redirecting money toward clinical programs capable of producing future revenue.
For shareholders, the distinction matters.
Cost cuts can boost earnings quickly, but indiscriminate reductions can damage product launches and scientific productivity. Pfizer’s long-term valuation will depend on whether it can protect R&D output while shrinking its expense base.
The $9.7 billion target could materially support margins and cash flow if achieved without disrupting the pipeline. It could also help Pfizer maintain its dividend as older products lose exclusivity.
Bourla said the company intends to preserve the payout and resume dividend increases after navigating its upcoming patent-expiration period.
COVID Revenue Is Still Collapsing
Pfizer’s earnings beat cannot hide the scale of the pandemic-product decline.
Paxlovid revenue plunged 95% during the second quarter, while sales of the Comirnaty COVID-19 vaccine dropped 34%. Pfizer attributed the weakness to lower infection rates and narrower vaccination recommendations.
The company now expects about $4 billion of combined 2026 revenue from COVID products, down from its previous $5 billion forecast.
That reduction explains why Pfizer’s overall revenue is barely growing despite strong performances from Eliquis, Padcev, Vyndaqel, and other medicines.
The pandemic temporarily transformed Pfizer into one of the world’s most profitable pharmaceutical companies. As that windfall disappears, investors are attempting to determine the company’s normalized earnings power.
The latest results suggest Pfizer can replace some of the lost revenue, but not all of it immediately.
Cost savings are therefore doing significant work. They can defend earnings while management waits for acquired products, internal research programs, and new indications for existing drugs to generate larger sales contributions.
Patent Expirations Create the Next Major Threat
COVID products are not Pfizer’s only revenue problem.
The company expects approximately $1.5 billion of negative revenue pressure in 2026 from medicines losing market exclusivity. That challenge is expected to intensify later in the decade as several major products face generic or biosimilar competition.
When a branded drug loses exclusivity, lower-priced competitors can capture market share rapidly. Revenue and margins may fall even if demand for the underlying treatment remains strong.
Pfizer must launch enough new products and indications to offset those declines.
The company has said stronger growth should return after 2028. Until then, investors may continue viewing PFE primarily as a dividend and restructuring story rather than a premium growth stock.
RBC Capital analyst Trung Huynh said the quarterly beat showed broad strength, but Pfizer still needs to deliver important clinical and commercial catalysts to regain credibility as a growth-focused pharmaceutical company.
That assessment captures the central market debate.
Pfizer can cut billions of dollars in costs, but it cannot cut its way to sustainable revenue growth. The pipeline must eventually take over.
Seagen Deal Produces Growth – and a $3.8 Billion Warning
Pfizer’s acquisition of Seagen is already contributing through medicines such as Padcev.
However, the deal also produced a painful reminder of biotechnology risk.
Pfizer recorded a $3.8 billion impairment charge tied to sigvotatug vedotin, an experimental lung cancer drug obtained through the Seagen acquisition. The charge contributed to a quarterly GAAP net loss of $248 million, or $0.04 per share, compared with a profit a year earlier.
The drug failed to improve overall survival in a late-stage study involving previously treated lung cancer patients.
Pfizer continues to test it in other settings, including a first-line combination with Merck’s Keytruda, but the impairment shows why investors cannot assume every acquired asset will justify its purchase price.
This creates a mixed verdict on Pfizer’s dealmaking.
Seagen’s approved medicines are helping revenue today, while one of its important pipeline programs has suffered a major setback. The ultimate return on the $43 billion acquisition will depend on continued growth from existing products and the success of remaining clinical assets.
Obesity Drugs Could Transform the PFE Stock Story
Pfizer’s $10 billion acquisition of Metsera gives the company another chance to build a major growth franchise.
The obesity-drug market is dominated by Eli Lilly and Novo Nordisk, but analysts believe annual global sales could eventually exceed $150 billion. Even a modest share could materially change Pfizer’s growth profile.
Berobenatide, Pfizer’s most advanced Metsera asset, is a once-monthly injection that produced weight loss of up to 12.3% in people without diabetes during a clinical study.
However, the treatment also raised tolerability questions, and investors will need more data before assuming it can compete successfully against established weekly injections or emerging oral therapies.
Metsera also brings amylin-based drug candidates that may offer differentiated efficacy, dosing, or tolerability.
Upcoming clinical results could become some of the most important catalysts for Pfizer stock. Positive data would give the company a credible route into one of healthcare’s fastest-growing markets; disappointing results would increase pressure on its oncology and internal-medicine pipeline.
Is Stock Cheap After Earnings?
At $25.41, Pfizer traded at approximately 19 times trailing earnings and carried a market capitalization near $146 billion after Tuesday’s gain.
Using the midpoint of Pfizer’s adjusted 2026 earnings guidance, the shares trade at roughly nine times expected adjusted earnings.
That forward multiple appears inexpensive relative to many large pharmaceutical peers, but the discount reflects real uncertainty.
Investors must account for falling COVID revenue, looming patent expirations, integration risk, clinical failures, pricing pressure, and the possibility that restructuring savings may not produce renewed sales growth.
The dividend remains a major attraction, especially for income-focused investors. Yet dividend security ultimately depends on free cash flow, not management’s stated intention alone.
The latest earnings report reduced immediate downside risk. It did not eliminate the longer-term need for successful launches and trial results.
Outlook: What Investors Should Watch Next
The Pfizer stock forecast has improved following the earnings beat, higher revenue midpoint, and expanded $9.7 billion savings target.
Investors should now monitor Eliquis and Vyndaqel growth, Seagen product sales, progress toward cost targets, free cash flow, the dividend, and the impact of patent expirations. Clinical results for mevrometostat, berobenatide, other Metsera obesity candidates, and Pfizer’s remaining oncology pipeline could determine whether the stock escapes its low-growth valuation.
Management says the company can return to stronger growth after 2028. Until then, Pfizer must show that restructuring is buying time for a genuine pipeline recovery—not merely making a shrinking business look more profitable.
The cost cuts are enormous, the valuation is low, and the dividend is tempting. The next clinical readout may decide whether Pfizer is finally rebuilding—or simply bracing for the cliff.
